



# Pharmaceuticals – Pipeline Overview<sup>1</sup> (as of July 25, 2025)

| Phase I                                                                                                                                                            |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>DGKzeta Inhibitor</b> (BAY 2965501)  ●                                         |
| <b>Lanerkitug</b> (CCR8 Ab) (BAY 3375968)  ●                                      |
| <b>VVD KEAP1 Act</b> (VVD-130037 aka <i>NRF2 Inh</i> , BAY 3605349)  ●            |
| <b>DGKalpha Inh</b> (BAY 2862789)  ●                                              |
| <b>225Ac-Pelgifatamab</b> (BAY 3546828)  ●                                        |
| <b>VVD STAT3 Inhibitor</b> (VVD-130850, BAY 3630914)  ●                           |
| <b>225Ac-PSMA-Trillium</b> (BAY 3563254)  ●                                       |
| <b>SOS1 Inhibitor</b> (BAY 3498264)  ●                                            |
| <b>PRMT5 Inhibitor</b> (BAY 3713372)  ●                                           |
| <b>VVD RAS-PI3K Inhibitor</b> (VVD-159642, BAY 3674171)  ●                        |
| <b>225Ac-GPC3</b> (BAY 3547926)  ●                                                |
| <b>VVD WRN Inhibitor</b> (VVD-214)  ●                                             |
| <b>SEMA 3a</b> (BAY 3401016)  ●                                                   |
| <b>Dual FIIa/Xa Inhibitor</b> (BAY 3389934)  ●                                    |
| <b>GIRK4 Inhibitor</b> (BAY 3670549) ●                                                                                                                             |
| <b>Bemdaneprocel</b> (Parkinson's Disease Cell Therapy) (BRT-DA01)  ●            |
| <b>Multiple System Atrophy rAAV Gene Therapy</b> (AB-1005 aka AAV2-GDNF-MSA)  ● |
| <b>Pompe Disease rAAV Gene Therapy</b> (ACTUS-101)  ●                           |
| <b>LGMD2I/R9 rAAV Gene Therapy</b> (AB-1003 aka LION-101)  ●                    |
| <b>GPR84 Antagonist</b> (BAY 3178275)  ●                                        |
| <b>BAY 2701250</b>  ●                                                           |
| <b>Primary Photoreceptor Diseases Cell Therapy</b> (BRT-OpCT-001)  ●            |

| Phase II                                                                                                                                                                                                                             |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Sevabertinib</b> (HER2/mEGFR Inhibitor) (BAY 2927088)  ○<br># Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (panSOHO) |
| <b>Congestive Heart Failure rAAV Gene Therapy</b> (AB-1002)  ●<br># Congestive Heart Failure (GenePHIT)                                           |
| <b>Anti-a2AP</b> (BAY 3018250)  ●<br># Acute Ischemic Stroke; Pulmonary Embolism (SIRIUS)                                                         |
| <b>Nurandociguat</b> (sGC Activator Oral) (BAY 3283142)  ●<br># Chronic Kidney Disease (ALPINE-1)                                                 |
| <b>Parkinson's Disease rAAV Gene Therapy</b> (AB-1005)  ●<br># Parkinson's Disease (REGENERATE-PD)                                                |

| Phase III                                                                                                                                                                                                                                                  |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Darolutamide</b> (AR Inhibitor)  ○<br># Adjuvant Prostate Cancer (DASL-HiCaP)<br># Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASTEP) |
| <b>Sevabertinib</b> (HER2/mEGFR Inhibitor)  ●<br># Advanced Non-small Cell Lung Cancer with HER2 Activating Mutations, 1L (SOHO-02)                                     |
| <b>Finerenone</b> (MR Antagonist)  ○<br># Non-diabetic Chronic Kidney Disease (FIND-CKD)<br># Chronic Kidney Disease in Type 1 Diabetes (FINE-ONE)                      |
| <b>Vericiguat</b> (sGC Stimulator)  ○<br># Heart Failure (HFrEF) (VICTOR <sup>2</sup> )                                                                                 |
| <b>Asundexian</b> (FXIa Inhibitor)  ●<br># 2° Stroke Prevention (OCEANIC-STROKE)                                                                                        |

| Submissions                                                                                                                                                                              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Darolutamide</b> (AR Inhibitor)  ○<br># CN: Prostate Cancer (mHSPC)                                |
| <b>Sevabertinib</b> (HER2/mEGFR Inhibitor)  ●<br># US, CN: HER2-mut NSCLC 2L                          |
| <b>Finerenone</b> (MR Antagonist)  ○<br># EU, CN, JP: Heart Failure (HFmr/pEF)                        |
| <b>Elinzanetant</b> (Neurokinin-1,3 Rec Antagonist)  ●<br># US, EU: Vasomotor Symptoms               |
| <b>Aflibercept 8mg</b> (VEGF-Inhibitor)  ○<br># EU, JP: Retinal Vein Occlusion                      |
| <b>Gadoquatrane</b> (High Relaxivity Contrast Agent)  ●<br># US, EU, JP: Magnetic Resonance Imaging |

|                                                                                       |                              |
|---------------------------------------------------------------------------------------|------------------------------|
|    | Oncology                     |
|    | Cardiovascular+ <sup>3</sup> |
|    | Neurology & Rare Diseases    |
|    | Immunology                   |
|    | Others                       |
|  | New molecular entity         |
|  | Life cycle management        |

 Protein Therapeutics  Cell Therapy  Contrast Agent  Genetic Medicine  Radionuclide Therapy  Small Molecule

<sup>1</sup> Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit  
<sup>2</sup> Conducted by Merck & Co <sup>3</sup> Including Precision Cardiovascular, Nephrology & Acute Care